Using next-generation sequencing to transform clinical practice
Session type: Parallel sessions
Next generation sequencing (NGS) technologies make the routine testing of both genetic predisposition to cancer and tumour-specific mutations a realistic aspiration for cancer care. Information about acquired and intrinsic genetic variation can inform diagnosis, classification and treatment, as well as risks of recurrence, secondary cancers and cancer risks in family members. Fundamental changes in health service infrastructure, workforce training, and clinician and public perceptions are required for the full promise to be realised. This session presents perspectives from the UK, Europe and the US regarding the processes, benefits and complexities of integrating somatic and germline genetic testing into routine oncological care.